No Data Yet
Guardant Health will present 14 studies at the 2025 San Antonio Breast Cancer Symposium on its liquid biopsy tests for breast cancer, aiming to validate their use in predicting recurrence and guiding treatment, positioning the company in the competitive oncology diagnostics market.
Guardant Health's stock fell 5.9% despite a strong quarter, after announcing a $634 million capital raise via convertible notes and a stock offering. The move signals an aggressive push for growth but sparked immediate concerns over shareholder dilution.
Guardant Health has partnered with Italy's Policlinico Gemelli to launch an in-house liquid biopsy service, embedding its advanced cancer diagnostics directly within a major European hospital. This move aims to accelerate turnaround times and improve access to precision oncology for patients with advanced cancer.
Guardant Health is partnering with Trial Library to integrate its precision oncology diagnostics with an AI-powered platform, aiming to broaden patient access to U.S. cancer clinical trials and streamline enrollment.
Bank of America Securities raised its price target for Guardant Health (GH) to $120 from $100, maintaining a "Buy" rating. The firm cites an expected market normalization and increased spending in the Biopharma sector projected for 2026.
While a select group of S&P 500 stocks delivered extraordinary gains in 2025, averaging 145% year-to-date, analysis reveals significant vulnerabilities for certain tech leaders. Investors are beginning to differentiate between business models, favoring recurring revenue streams over those dependent on cyclical capital expenditures, signaling a potential market shift.